Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $45 to $46.
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.